Aerpio Pharmaceuticals, Inc. (ARPO) Analysts See $-0.23 EPS

August 12, 2018 - By Benjamin Allen

Analysts expect Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) to report $-0.23 EPS on August, 21.After having $-0.27 EPS previously, Aerpio Pharmaceuticals, Inc.’s analysts see -14.81 % EPS growth. The stock increased 8.63% or $0.29 during the last trading session, reaching $3.65. About 4,392 shares traded. Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) has 0.00% since August 13, 2017 and is . It has underperformed by 12.57% the S&P500.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company has market cap of $141.45 million. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It currently has negative earnings. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease.

More recent Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” on August 08, 2018. Also Benzinga.com published the news titled: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs” on August 12, 2018. Streetinsider.com‘s news article titled: “Needham & Company Starts Aerpio Pharmaceuticals (ARPO) at Buy” with publication date: July 23, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.